Hello All,
Attached are the fact sheets for patients for the new emergency use authorization drug Evusheld and Sotrovimab. Read carefully and feel free to share with anyone and everyone. If you know someone who is immune compromise or who has received Immuno suppressive medications, at least the information provided are some talking points for conversations to have with their medical team.
Sabrina
EVUSHELD
Fact Sheet for Patients, Parents And Caregivers Emergency Use Authorization (EUA) of EVUSHELDTM (tixagevimab co-packaged with cilgavimab) for Coronavirus Disease 2019 (COVID-19)
You are being given this Fact Sheet because your healthcare provider believes it is necessary to provide you with EVUSHELD (tixagevimab co-packaged with cilgavimab) for pre-exposure prophylaxis for prevention of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus.
This Fact Sheet contains information to help you understand the potential risks and potential benefits of taking EVUSHELD, which you have received or may receive.
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to make EVUSHELD available during the COVID-19 pandemic (for more details about an EUA please see “What is an Emergency Use Authorization?” at the end of this document). EVUSHELD is not an FDA-approved medicine in the United States.
Read this Fact Sheet for information about EVUSHELD. Talk to your healthcare provider if you have any questions. It is your choice to receive or not receive EVUSHELD.
What is COVID-19?
COVID-19 is caused by a virus called a coronavirus. You can get COVID-19 through close contact with another person who has the virus.
COVID-19 illnesses have ranged from very mild (including some with no reported symptoms) to severe, including illness resulting in death. While information so far suggests that most COVID-19 illness is mild, serious illness can happen and may cause some of your other medical conditions to become worse. Older people and people of all ages with severe, long-lasting (chronic) medical conditions like heart disease, lung disease, and diabetes, for example, seem to be at higher risk of being hospitalized for COVID-19.
What is EVUSHELD (tixagevimab co-packaged with cilgavimab)?
EVUSHELD is an investigational medicine used in adults and adolescents (12 years of age and older who weigh at least 88 pounds [40 kg]) for pre- exposure prophylaxis for prevention of COVID-19 in persons who are:
• not currently infected with SARS-CoV-2 and who have not had recent known close contact with someone who is infected with SARS-CoV-2 and
o Who have moderate to severe immune compromise due to a medical condition or have received immunosuppressive medicines or treatments and may not mount an adequate immune response to COVID-19 vaccination or
o For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (such as severe allergic reaction) to a COVID-19 vaccine(s) or COVID-19 vaccine ingredient(s).
EVUSHELD is investigational because it is still being studied. There is limited information known about the safety and effectiveness of using EVUSHELD for pre-exposure prophylaxis for prevention of COVID-19. EVUSHELD is not authorized for post-exposure prophylaxis for prevention of COVID-19.
The FDA has authorized the emergency use of EVUSHELD for pre-exposure prophylaxis for prevention of COVID-19 under an Emergency Use Authorization (EUA).
What should I tell my healthcare provider before I receive EVUSHELD? Tell your healthcare provider if you:
• Have any allergies
• Have low numbers of blood platelets (which help blood clotting), a bleeding
disorder, or are taking anticoagulants (to prevent blood clots)
• Have had a heart attack or stroke, have other heart problems, or are at high-
risk of cardiac (heart) events
• Are pregnant or plan to become pregnant
• Are breastfeeding a child
• Have any serious illness
• Are taking any medications (prescription, over-the-counter, vitamins, or herbal
products)
How will I receive EVUSHELD?
• EVUSHELD consists of two investigational medicines, tixagevimab and cilgavimab.
• You will receive 1 dose of EVUSHELD, consisting of 2 separate injections (tixagevimab and cilgavimab).
• EVUSHELD will be given to you by your healthcare provider as 2 intramuscular injections. They are usually, given one after the other, 1 into each of your buttocks.
After the initial dose, if your healthcare provider determines that you need to receive additional doses of EVUSHELD for ongoing protection, the additional doses would be administered once every 6 months.
Who should generally not take EVUSHELD?
Do not take EVUSHELD if you have had a severe allergic reaction to EVUSHELD or any ingredient in EVUSHELD.
What are the important possible side effects of EVUSHELD?
Possible side effects of EVUSHELD are:
• Allergic reactions. Allergic reactions can happen during and after injection of EVUSHELD. Tell your healthcare provider right away if you get any of the following signs and symptoms of allergic reactions: fever, chills, nausea, headache, shortness of breath, low or high blood pressure, rapid or slow heart rate, chest discomfort or pain, weakness, confusion, feeling tired, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, dizziness and sweating. These reactions may be severe or life threatening.
• Cardiac (heart) events: Serious cardiac adverse events have happened, but were not common, in people who received EVUSHELD and also in people who did not receive EVUSHELD in the clinical trial studying pre-exposure prophylaxis for prevention of COVID-19. In people with risk factors for cardiac events (including a history of heart attack), more people who received EVUSHELD experienced serious cardiac events than people who did not receive EVUSHELD. It is not known if these events are related to EVUSHELD or underlying medical conditions. Contact your healthcare provider or get medical help right away if you get any symptoms of cardiac events, including pain, pressure, or discomfort in the chest, arms, neck, back, stomach or jaw, as well as shortness of breath, feeling tired or weak (fatigue), feeling sick (nausea), or swelling in your ankles or lower legs.
The side effects of getting any medicine by intramuscular injection may include pain, bruising of the skin, soreness, swelling, and possible bleeding or infection at the injection site.
These are not all the possible side effects of EVUSHELD. Not a lot of people have been given EVUSHELD. Serious and unexpected side effects may happen. EVUSHELD is still being studied so it is possible that all of the risks are not known at this time.
It is possible that EVUSHELD may reduce your body’s immune response to a COVID-19 vaccine. If you have received a COVID-19 vaccine, you should wait to receive EVUSHELD until at least 2 weeks after COVID-19 vaccination.
What other prevention choices are there?
Vaccines to prevent COVID-19 are approved or available under Emergency Use Authorization. Use of EVUSHELD does not replace vaccination against COVID-19. For more information about other medicines authorized for treatment or prevention of COVID-19 go to https://www.fda.gov/emergency-
It is your choice to receive or not receive EVUSHELD. Should you decide not to receive EVUSHELD, it will not change your standard medical care.
EVUSHELD is not authorized for post-exposure prophylaxis of COVID-19.
What if I am pregnant or breastfeeding?
If you are pregnant or breastfeeding, discuss your options and specific situation with your healthcare provider.
How do I report side effects with EVUSHELD?
Contact your healthcare provider if you have any side effects that bother you or do not go away. Report side effects to FDA MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088 or call AstraZeneca at 1-800-236-9933.
Additional Information
If you have questions, visit the website or call the telephone number provided below.
To access the most recent EVUSHELD Fact Sheets, please scan the QR code provided below. Website Telephone number
How can I learn more about COVID-19?
• Ask your healthcare provider.
• Visit https://www.cdc.gov/COVID19
• Contact your local or state public health department.
What is an Emergency Use Authorization?
The United States FDA has made EVUSHELD (tixagevimab co-packaged with cilgavimab) available under an emergency access mechanism called an Emergency Use Authorization EUA. The EUA is supported by a Secretary of Health and Human Service (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.
EVUSHELD for pre-exposure prophylaxis for prevention of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus has not undergone the same type of review as an FDA-approved product. In issuing an EUA under the COVID-19 public health emergency, the FDA has determined, among other things, that based on the total amount of scientific evidence available including data from adequate and well- controlled clinical trials, if available, it is reasonable to believe that the product may be effective for diagnosing, treating, or preventing COVID-19, or a serious or life- threatening disease or condition caused by COVID-19; that the known and potential benefits of the product, when used to diagnose, treat, or prevent such disease or condition, outweigh the known and potential risks of such product; and that there are no adequate, approved and available alternatives.
All of these criteria must be met to allow for the product to be used in the treatment of patients during the COVID-19 pandemic. The EUA for EVUSHELD is in effect for the duration of the COVID-19 declaration justifying emergency use of EVUSHELD,
1-800-236-9933
SOTROVIMAB
FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS Emergency Use Authorization (EUA) of Sotrovimab for the Treatment of Coronavirus Disease 2019 (COVID-19)
You are being given a medicine called sotrovimab for the treatment of coronavirus disease 2019 (COVID-19). This Fact Sheet contains information to help you understand the potential risks and potential benefits of taking sotrovimab, which you may receive.
Receiving sotrovimab may benefit certain people with COVID-19.
Read this Fact Sheet for information about sotrovimab. Talk to your healthcare provider if you have any questions. It is your choice to receive sotrovimab or stop it at any time.
What is COVID-19?
COVID-19 is caused by a virus called a coronavirus. People can get COVID-19 through contact with another person who has the virus.
COVID-19 illnesses have ranged from very mild (including some with no reported symptoms) to severe, including illness resulting in death. While information so far suggests that most COVID-19 illness is mild, serious illness can happen and may cause other medical conditions to become worse. People of all ages with severe, long-lasting (chronic) medical conditions like heart disease, lung disease, diabetes, for example, and other conditions including obesity, seem to be at higher risk of being hospitalized for COVID-19. Older age, with or without other conditions, also places people at higher risk of being hospitalized for COVID-19.
What are the symptoms of COVID-19?
The symptoms of COVID-19 are fever, cough, and shortness of breath, which may appear 2 to 14 days after exposure. Serious illness, including breathing problems, can occur and may cause your other medical conditions to become worse.
What is sotrovimab?
Sotrovimab is an investigational medicine used to treat mild-to-moderate symptoms of COVID-19 in adults and children (12 years of age and older weighing at least 88 pounds [40 kg]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk of progression to severe COVID-19, including hospitalization or death. Sotrovimab is investigational because it is still being studied. There is limited information about the safety and effectiveness of using sotrovimab to treat people with mild-to-moderate COVID-19.
The U.S. Food & Drug Administration (FDA) has authorized the emergency use of sotrovimab for the treatment of COVID-19 under an Emergency Use Authorization (EUA). For more information on EUA, see the “What is an Emergency Use Authorization (EUA)?” section at the end of this Fact Sheet.
Who should not receive sotrovimab?
Do not take sotrovimab if you have had a serious allergic reaction to sotrovimab or to any of the ingredients in sotrovimab.
What are the ingredients in sotrovimab?
Active ingredient: sotrovimab
Inactive ingredients: L-histidine, L-histidine monohydrochloride, L-methionine, polysorbate 80, and sucrose
What should I tell my healthcare provider before I receive sotrovimab?
Tell your healthcare provider about all of your medical conditions, including if you:
• Have any allergies
• Have had a serious allergic reaction to sotrovimab or to any of the ingredients in sotrovimab
• Are pregnant or plan to become pregnant
1
• Are breastfeeding or plan to breastfeed
• Have any serious illnesses
• Are taking any medicines (prescription, over-the-counter, vitamins, or herbal products)
How will I receive sotrovimab?
• You will receive 1 dose of sotrovimab.
• Sotrovimab will be given to you through a vein (intravenous or IV infusion) over 30 minutes.
• You will be observed by your healthcare provider for at least 1 hour after you receive sotrovimab.
What are the important possible side effects of sotrovimab?
Possible side effects of sotrovimab are:
• Allergic reactions. Allergic reactions can happen during and after infusion with sotrovimab. Tell your healthcare provider right away if you get any of the following signs and symptoms of allergic reactions: fever; difficulty breathing; low oxygen level in your blood; chills; tiredness; fast or slow heart rate; chest discomfort or pain; weakness; confusion; nausea; headache; shortness of breath; low or high blood pressure; wheezing; swelling of your lips, face, or throat; rash including hives; itching; muscle aches; dizziness; feeling faint; and sweating.
The side effects of getting any medicine through a vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.
These are not all the possible side effects of sotrovimab. Not many people have been given sotrovimab. Serious and unexpected side effects may happen. Sotrovimab is still being studied, so it is possible that all of the risks are not known at this time.
It is possible that sotrovimab could interfere with your body’s own ability to fight off a future infection of SARS-CoV-2. Similarly, sotrovimab may reduce your body’s immune response to a vaccine for SARS- CoV-2. Specific studies have not been conducted to address these possible risks. Talk to your healthcare provider if you have any questions.
What other treatment choices are there?
Like sotrovimab, FDA may allow for the emergency use of other medicines to treat people with COVID- 19. Go to https://www.fda.gov/emergency-
It is your choice to be treated or not to be treated with sotrovimab. Should you decide not to receive sotrovimab, or stop it at any time, it will not change your standard medical care.
What if I am pregnant or breastfeeding?
There is no experience treating pregnant women or breastfeeding mothers with sotrovimab. For a mother and unborn baby, the benefit of receiving sotrovimab may be greater than the risk from the treatment. If you are pregnant or breastfeeding, discuss your options and specific situation with your healthcare provider.
How do I report side effects with sotrovimab?
Tell your healthcare provider right away if you have any side effects that bother you or do not go away.
Report side effects to FDA MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088, or call the GSK COVID Contact Center at 1-866-GSK-COVID (866-475-2684).
How can I learn more?
• Ask your healthcare provider
• Visit www.sotrovimabinfo.com
• Call the GSK COVID Contact Center at 1-866-GSK-COVID (866-475-2684)
2
• Contact your local or state public health department
What is an Emergency Use Authorization (EUA)?
The FDA has made sotrovimab available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Service (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.
Sotrovimab has not undergone the same type of review as an FDA-approved medicine. In issuing an EUA under the COVID-19 public health emergency, the FDA must determine, among other things, that based on the totality of scientific evidence available, it is reasonable to believe that the product may be effective for diagnosing, treating, or preventing COVID-19, or a serious or life-threatening disease or condition caused by COVID-19; that the known and potential benefits of the product, when used to diagnose, treat, or prevent such disease or condition, outweigh the known and potential risks of such product; and that there are no adequate, approved and available alternatives. All of these criteria must be met to allow for the medicine to be used in the treatment of patients during the COVID-19 pandemic.
The EUA for sotrovimab is in effect for the duration of the COVID-19 declaration justifying emergency use
ReplyReply allForward |
No comments:
Post a Comment